Results 61 to 70 of about 186,128 (186)

Anti-vascular endothelial growth factor for diabetic macular oedema. [PDF]

, 2014
BACKGROUND: Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Although grid or focal laser photocoagulation has been shown to reduce the risk of visual loss in DMO, or clinically significant macular oedema (CSMO), vision is ...
Evans, Jennifer R, Menchini, Francesca, Parravano, Mariacristina, Virgili, Gianni   +3 more
core   +1 more source

Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry [PDF]

, 2022
Purpose To compare the outcomes of two different antivascular endothelial growth factor treatment regimens for treatment-naive eyes with neovascular age-related macular degeneration in routine clinical care at 12 and 24 months in Spain.
Barthelmes, Daniel, Casaroli Marano, Ricardo Pedro, Figueras Roca, Marc, Gillies, Mark C., Moll Udina, Aina, Nguyen, Vuong, Parrado Carrillo, Alba, Zarranz Ventura, Javier   +7 more
core   +1 more source

Treat-And-Extend Regimens with Anti-Vegf Agents in Retinal Diseases

Retina, 2015
PURPOSE: A review of treat-and-extend regimens (TERs) with intravitreal anti-vascular endothelial growth factor agents in retinal diseases. METHODS: There is a lack of consensus on the definition and optimal application of TER in clinical practice. This article describes the supporting evidence and subsequent development of a generic algorithm for TER ...
Freund, K. Bailey, Korobelnik, Jean François, Devenyi, Robert, Framme, Carsten, Galic, John, Herbert, Edward, Hoerauf, Hans, LANZETTA, Paolo, Michels, Stephan, Mitchell, Paul, Monés, Jordi, Regillo, Carl, Tadayoni, Ramin, Talks, James, Wolf, Sebastian   +14 more
openaire   +5 more sources

Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion [PDF]

Ophthalmology Retina
To assess the efficacy, durability, and safety of dual angiopoietin-2/VEGF inhibition with faricimab dosed per a modified treat-and-extend-based regimen in patients with retinal vein occlusion.Single-arm treatment period after a randomized, double-masked,
Carl J. Danzig, Christiana Dinah, Faruque Ghanchi, Lars-Olof Hattenbach, Arshad M. Khanani, Timothy Y.Y. Lai, Masahiko Shimura, Francis Abreu, Pablo Arrisi, Ying Liu, Liliana P. Paris, Anne-Cecile Retiere, Jeffrey R. Willis, Patricio G. Schlottmann, Ashkan Abbey, Elmira Abdulaeva, Santiago Abengoechea, Prema Abraham, Sean Adrean, Hansjürgen Agostini, Arturo Alezzandrini, Daniel Alfaro, Socorro Alforja, Daniel Aliseda, Goncalo Almeida, Payam Amini, Liangbao An, Etelka Aradi, Luis Arias, Sergei Astakhov, Carl Awh, Bulat Aznabaev, Joaquin Bafalluy, Chandra Balaratnasingam, Francesco Bandello, Sanjiv Banerjee, Mark Barakat, Andres Bastien, Ivan Batlle, Rubens Belfort, Brian Berger, Emilia Borcz, Arnaldo Bordon, Michael Briggs, Harold Brooks, David Brown, Jamin Brown, Jacek Brymerski, Maria Budzinskaya, Stuart Burgess, Iksoo Byon, Peter Campochiaro, Andrew Chang, Emmanuel Chang, Caroline Chee, Changzheng Chen, Judy Chen, Shih-Jen Chen, Nicholas Chinskey, Oldrich Chrapek, Salomon Yves Cohen, Juner Colina-Biscotto, Brian Connolly, Pierre Loic Cornut, Hajir Dadgostar, Hong Dai, Carl Danzig, Anthony de Beus, Mario R. del Cid, Amr Dessouki, Christiana Dinah, Antonio Donate, David Eichenbaum, Jan Ernest, Joan Josep Escobar, Andrej Farkas, Nicolas Feltgen, Gloria Ferguson, Philip Ferrone, Joao Figueira, Marta Figueroa, Pablo Franco, Samantha Fraser-Bell, Nicholas Siu Kay Fung, Roberto Gallego-PInazo, Alfredo Garcia-Layana, Maciej Gawecki, Nicola Gan, Faruque Ghanchi, Ghassan Ghorayeb, Fabrizio Giansanti, Manjot Gill, Michaella Goldstein, Fumi Gomi, Jordan Graff, Shailesh Gupta, Mei Han, Ryuya Hashimoto, Lars-Olof Hattenbach, Ken Hayashi, Lina Kobayter Helayhel, Ewa Herba, Vrinda Hershberger, Patrick Higgins, Takao Hirano, Yoshio Hirano, Shigeru Honda, Allen Hu, Stephen Huddleston, Alan A. Hunter, Yih-Shiou Hwang, Tomohiro Iida, Yuichiro Ishida, Golnaz Javey, Cameron Javid, Jakub Kaluzny, Hiroki Kaneko, Se Woong Kang, Hakan Kaymak, Patrick Kelty, Agnes Kerenyi, Arshad Khanani, Rahul Khurana, Jong Woo Kim, Sang Jin Kim, Genichiro Kishino, Namie Kobayashi, Lina Kobayter Helayhel, Bohdan Kousal, Robert Kwun, Alexey Kulikov, Ajay Kuriyan, James Lai, Yuk Yau Timothy Lai, Wai Ching Lam, Daniel Lavinsky, Seong Lee, Xiaorong Li, Xiaoling Liang, Lucas Lindsell, Nikolas London, Peck-Lin Lip, Mimi Liu, Xiaoling Liu, Alan Luckie, Miguel Lume, James K. Luu, Dennis Marcus, Yoshitsugu Matsui, Hemal Mehta, Katarzyna Michalska-Malecka, Yoshinori Mitamura, Quresh Mohamed, Aditi Mohla, Javier Montero, Jeffrey Moore, Ryusaburo Mori, Haia Morori-Katz, Raj Mukherjee, Yuki Muraoka, Maria Muzyka-Wozniak, Jan Nemcansky, Tetsuya Nishimura, Hideyasu Oh, Piotr Oleksy, Kyu Hyung Park, D. Wilkin Parke, Maria Cristina Parravano, Apurva Patel, Sunil Patel, Marc Peden, Fernando Penha, Qing Peng, Nadezhda Pozdeyeva, Dorota Raczynska, Hessam Razavi, Gayatri Reilly, Marek Rekas, Federico Ricci, Richard Roe, Soraya Rofagha, Bozena Romanowska-Dixon, Irit Rosenblatt, Jose Maria Ruiz Moreno, Stefan Sacu, Min Sagong, Yoshitsugu Saishin, Taiji Sakamoto, Sukhpal Sandhu, Laura Sararols, Mario Saravia, Patricio Schlottmann, Tetsuju Sekiryu, András Seres, Ankur Shah, Veeral Sheth, Masahiko Shimura, Bartosz Sikorski, Rufino Silva, Zongming Song   +199 more
openaire   +3 more sources

Treat‐and‐extend versus every‐other‐month regimens with aflibercept in age‐related macular degeneration [PDF]

Acta Ophthalmologica, 2017
AbstractPurposeTo compare the 1‐year outcomes of treat‐and‐extend (TAE) and every‐other‐month (2M) regimens with intravitreal aflibercept in Japanese wet age‐related macular degeneration (AMD) patients.MethodsProspective, multicenter, randomized clinical trial.
Akira Haga, Takahiro Kawaji, Ryuichi Ideta, Yasuya Inomata, Hidenobu Tanihara   +4 more
openaire   +2 more sources

Management of wet age-related macular degeneration in Spain: challenges for treat and extend implementation in routine clinical practice [PDF]

, 2019
Age-related macular degeneration; Ophthalmology services; Anti-VEGFDegeneración macular relacionada con la edad; Servicios de oftalmología; Anti-VEGFDegeneració macular relacionada amb l’edat; Serveis d’oftalmologia; Anti-VEGFPurpose.
Arias Barquet, L., Figueroa, M. S., García Arumí, José, García-Layana, A., Monclús-Arbona, L., Ruíz-Moreno, J. M.   +5 more
core   +1 more source

Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration [PDF]

, 2018
Purpose: To investigate the rhythm and predictability of the need for retreatment with intravitreal injections of ranibizumab for neovascular age-related macular degeneration (nAMD).
Ambresin, Aude, Deli, Angeliki, Iglesias, Katia, Mantel, Irmela   +3 more
core  

Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05

, 2016
Background: To investigate intravitreal treatment efficiencies in patients suffering from exudative ARMD with a BCVA ≤ 0.05. Methods: Retrospective analysis: Analysis parameters were lesion type, BCVA at baseline and at follow-up, the intravitreal drug ...
Busse, H. (Holger), Gebauer, S.M.I. (Sabine), Koch, R. (Raphael), Schmidt, M. (Matthias), Uhlig, C. (Constantin)   +4 more
core   +1 more source

Two-Year Outcomes of “Treat and Extend” Intravitreal Therapy for Neovascular Age-Related Macular Degeneration

Ophthalmology, 2015
To report 24-month outcomes of anti-vascular endothelial growth factor (VEGF) therapy for treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) using a treat and extend treatment regimen in routine clinical practice.Database observational study.We included treatment-naïve eyes receiving predominantly ranibizumab for nAMD in ...
Jennifer J. Arnold, Anna Campain, Daniel Barthelmes, Judy M. Simpson, Robyn H. Guymer, Alex P. Hunyor, Ian L. McAllister, Rohan W. Essex, Nigel Morlet, Mark C. Gillies, A. Hunt, M. Gillies, A. Hunt, A.P. Hunyor, J. Arnold, S. Young, G. Clark, Gayatri Banerjee, R. Phillips, M. Perks, R. Essex, I. McAllister, I. Constable, R. Guymer, R. Guymer, L. Lim, A. Harper, L.P. Chow, S. Wickremansinghe, S. Wickremasinghe, S. Wickremasinghe   +30 more
openaire   +5 more sources

Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial. [PDF]

, 2020
PURPOSE:To evaluate efficacy and safety of intravitreal injections of aflibercept (IVT-AFL) treat-and-extend (T&E) dosing regimens in treatment-naïve patients with exudative age-related macular degeneration (AMD).METHODS:Adults aged at least 50 years old
ALTAIR Investigators, HANEMOTO Tsukasa, HORIGUCHI Masayuki, KAGA Tatsushi, KAWAHARA Akiteru, KIMURA Wataru, KITAMEI Hirokuni, Kobayashi Masato, KOBAYASHI Namie, KOUNO Takeya, KURIMOTO Yasuo, MAENO Takatoshi, MATSUDA Yoshimi, MATSUSHITA Eriko, MIYATA Kazunori, MURAI Kenichi, NISHIMURA Tetsuya, OHJI Masahito, OKADA Annabelle Ayame, SATO Shinpei, SONODA Kohei, TAKAHASHI Kanji, TERANO Yasuhiro, Uchio Eiichi, YANAI Ryoji, YASUKAWA Tsutomu, 大路 正人, 若林 賢彦   +27 more
core   +2 more sources